Paclitaxel

Where the papers sit

49 papers from the last 6 months study paclitaxel directly · updated from PubMed 12 Oct 2026

• Targeted Nanotherapy and Resistance

  Targeted nanotherapy is being used to improve paclitaxel delivery across lung, ovarian, pancreatic, breast, liver and nasopharyngeal cancers. Hypoxia-responsive release, photothermal or sonodynamic activation, inhalation and stromal targeting recur as ways to increase tumor exposure. Apoptosis, reactive oxygen species, mitochondrial-immune signaling and tumor microenvironment remodeling provide recurring mechanistic endpoints. Combination therapy is favored, but chemoresistance involving hexokinase 2, sphingomyelin synthesis and stromal remodeling remains an open barrier.

  18 papers · 36.7%

• Triple-Negative Breast Cancer Therapy

  Triple-negative breast cancer treatment is moving toward chemoimmunotherapy, targeted combinations and drug-delivery systems rather than paclitaxel alone. Durvalumab, atezolizumab, bevacizumab, capivasertib and oleclumab recur alongside chemotherapy, with immune dynamics and cytotoxicity informing response. Nanocarriers and co-delivery strategies aim to improve tumor exposure while limiting systemic toxicity. Resistance remains linked to SCYL1 phosphorylation and PI3K/AKT/mTOR signaling, while clinical comparisons continue to weigh survival and safety.

  11 papers · 22.4%

• Self-Assembled Drug Delivery

  Self-assembled liposomes, ionic-liquid aggregates and polymeric nanoplatforms are being tuned to increase cellular uptake and control paclitaxel release. Particle size, zeta potential and encapsulation efficiency recur as practical determinants of performance, while BODIPY systems add reductive-environment reporting. Combination designs with andrographolide or melittin seek dose reduction and synergistic cytotoxicity in cancer and keloid disease. Clinical pharmacokinetic work adds an emphasis on oral formulation behavior and food effects.

  7 papers · 14.3%

• Protein-Based Drug Delivery

  Protein and cyclodextrin conjugates are being developed to solubilize and transport hydrophobic anticancer drugs. Bovine serum albumin, γ-cyclodextrin, hyaluronic acid and PAMAM dendrimers recur as carriers, with Abraxane serving as a clinical benchmark. Studies emphasize binding, biophysical compatibility, cytotoxicity and delivery performance in cell models. The field is moving toward ligand-targeted systems, including CD44-directed delivery of gemcitabine and paclitaxel for pancreatic cancer.

  4 papers · 8.2%

• Others — Cancer Chemotherapy Outcomes

  Clinical chemotherapy studies span cervical, thyroid, esophageal, endometrial, salivary, nasopharyngeal and lung cancers, with carboplatin or cisplatin frequently paired with taxane treatment. Complete response, survival, conversion surgery and treatment feasibility are recurring endpoints, including therapy during pregnancy and HER2-directed treatment. Immunotherapy and targeted therapy appear in selected settings, but the studies do not establish one consistent treatment direction. Paclitaxel-induced peripheral neuropathy and economic evaluation broaden the cluster beyond efficacy alone.

  9 papers · 18.4%